Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

JJA (Johannes) Auwerda, Y Yuana, S Osanto, Moniek de Maat, Pieter Sonneveld, RM Bertina, Frank Leebeek

Research output: Contribution to journalArticleAcademicpeer-review

108 Citations (Scopus)


Multiple myeloma (MM) is associated with an increased risk of venous, thromboembolic (VIE) complications. Aim of this study was to measure microparticle-associated tissue factor (MP-TF) activity in patients with newly diagnosed MM before and after chemotherapy and to investigate whether MP-IF activity is associated with VTE. MP-IF activity was; assessed in 122 newly diagnosed MM patients who were eligible for combination chemotherapy. MP-TF activity levels (17.6 fM Xa/min; [8.6-33.2] (median [IQR]) were higher in untreated MM patients compared to normal healthy volunteers (4.1 fM Xa/min [2.3-6.6], p <0.001). MP-IF activity prior to the start of treatment was not different between patients who developed a VTE during follow-up (n=15) and those who did not (n=107). In 75 patients in whom plasma was obtained before and after chemotherapy, MP-IF activity decreased significantly (from 17.4 [10.2-32.8] to 12.0 [7.0-18.5] fM Xa/min, P=0.006). MP-IF activity remained, however, elevated in patients who developed VIE (15.1 [10.3-25.2]), in contrast to patients not developing VIE (11.4 [7.0-25.2], P<0.001). In conclusion, MP-IF activity is increased in patients with MM. Whether MP-IF activity has a pathogenetic role in VIE in MM patients remains to be established in future studies.
Original languageUndefined/Unknown
Pages (from-to)14-20
Number of pages7
JournalThrombosis and Haemostasis
Issue number1
Publication statusPublished - 2011

Research programs

  • EMC COEUR-09

Cite this